Neutralizing Potency Measured in Cell-Based Assay

EB Els Beirnaert
AD Aline Desmyter
SS Silvia Spinelli
ML Marc Lauwereys
LA Lucien Aarden
TD Torsten Dreier
RL Remy Loris
KS Karen Silence
CP Caroline Pollet
CC Christian Cambillau
HH Hans de Haard
request Request a Protocol
ask Ask a question
Favorite

The TNF sensitive mouse fibroblast cell line L929s was utilized for measuring the anti-TNF activity of the selected Nanobodies™. L929 cells were grown until nearly confluent, plated out in 96-well microtiter plates at 5,000 cells per well, and incubated overnight. Actinomycin D was added to the cells at a final concentration of 1 µg/ml. Serial dilutions of the Nanobodies™ to be tested were mixed with a cytotoxic concentration of TNF (10 pM). After incubation for 30 min at 37°C, this mixture was added to the plated cells and incubated for 24 h at 37°C. Cell viability was determined by using the tetrazolium salt WST-1. Dose–response curves and IC50 values (potency) were calculated with GraphPad Prism. The mean potencies for individual Nanobody™ constructs and benchmark anti-TNF biologics were calculated from a number of independent bioassays as well as the SD.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A